Danube Pharmaceuticals Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Danube Pharmaceuticals Inc.
The New Ophthalmic Drug Players
Unmet medical need and market size continue to drive venture investors to ophthalmic drug plays focused on diseases that blind.
The New Ophthalmic Drug Players
Unmet medical need and market size continue to drive venture investors to ophthalmic drug plays focused on diseases that blind. This interest is fueled by a stable pool of acquirers and the ability to in-license innovative, clinically validated compounds, providing VCs with a jump start to a potential exit.
Start-Up Previews (7/06)
A preview of the emerging health care companies profiled in the current, all profiles issue of Start-Up. This month's profile groups: Post-Macugen, Still In-Licensing to Uncover Value in Ophthalmology, Neurostimulation's Billion Dollar Markets, and Antibacterial Drug Development. Plus these Start-Up Across Health Care: Ascenta Therapeutics, CircuLite, CoroNovative and Endovalve.
Danube Pharmaceuticals Inc.
Biotech start-up Danube Pharmaceuticals Inc. has in-licensed what it calls the only dual-mechanism of action, orally available small molecule in clinical testing for glaucoma, a leading cause of irreversible blindness worldwide.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Drug Delivery
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice